GENELUX Corp PE Ratio
The price-to-earnings (P/E) ratio tells you how many dollars investors pay for each dollar of a company's annual profit. It is market capitalization divided by net income over the trailing four quarters, meaning the four most recent filed quarters added together, and the table shows both amounts. A higher P/E means investors are paying more for each dollar of current earnings, often because they expect profits to grow; a negative P/E means the company lost money over those four quarters. Each point uses the filed share count and the last closing price on or before that quarter-end date, never today's price.
- GENELUX Corp pe ratio for the quarter ending 2026-06-30 was -3.83, a change of -0.22 year-over-year.
- GENELUX Corp pe ratio for the quarter ending 2026-03-31 was -3.22, a change of 0.23 year-over-year.
- GENELUX Corp pe ratio for the quarter ending 2025-12-31 was -5.17, a change of -2.42 year-over-year.
- GENELUX Corp pe ratio for the quarter ending 2025-09-30 was -5.03, a change of -2.07 year-over-year.
- GENELUX Corp pe ratio for fiscal 2026 was -3.83.
- GENELUX Corp pe ratio for fiscal 2025 was -5.17, a change of -2.42 from fiscal 2024.
- GENELUX Corp pe ratio for fiscal 2024 was -2.74, a change of 10.52 from fiscal 2023.
- GENELUX Corp pe ratio for fiscal 2023 was -13.26.
- Available history
- 2023-03-31 to 2026-06-30
- Data captured
Historical PE Ratio
Annual PE Ratio
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| ProMIS Neurosciences Inc. (PMN) | $0.102B | ||
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| Coya Therapeutics, Inc. (COYA) | United States | $0.121B | -6.35 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |